In the BioHarmony Drug Report Database
Betibeglogene autotemcel
Zynteglo (betibeglogene autotemcel) is a gene pharmaceutical. Betibeglogene autotemcel was first approved as Zynteglo on 2019-05-29. It has been approved in Europe to treat beta-thalassemia.
Trade Name
|
Zynteglo |
|---|---|
Common Name
|
betibeglogene autotemcel |
ChEMBL ID
|
CHEMBL4594311 |
Indication
|
beta-thalassemia |
Drug Class
|
Image (chem structure or protein)
